CERo Therapeutics Holdings, Inc.
CEROOTCHealthcare● Active
$0.01
$-0.00(-13.64%)
Market Cap$12596
P/E Ratio—
52W High$26.99
52W Low$0.01
CERo Therapeutics Holdings, Inc. (CERO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CERO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.20
Est. -$0.80 · +75.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
CERO reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.80 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.80 | -$0.20 | +75.0% | — | — | — |
| — Q1 FY2026 | Feb 25, 2026 | -$0.75 | -$0.75 | +0.0% | — | — | — |
| ▼ Q4 FY2025 | Nov 19, 2025 | -$0.76 | -$9.10 | -1097.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 22, 2025 | -$124.26 | -$61.71 | +50.3% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$5.96 | -$1.59 | +73.3% | — | — | — |
| — Q2 FY2025 | Apr 1, 2025 | — | -$1.75 | — | — | — | — |
| — Q4 FY2024 | Nov 19, 2024 | — | -$180.00 | — | — | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.80
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.20
EPS Est.
-$0.80
EPS Surpr.
+75.0%
Revenue
—
Q1 FY2026
Feb 25, 2026
EPS Actual
-$0.75
EPS Est.
-$0.75
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2025
Nov 19, 2025Miss
EPS Actual
-$9.10
EPS Est.
-$0.76
EPS Surpr.
-1097.4%
Revenue
—
Q3 FY2025
Aug 22, 2025Beat
EPS Actual
-$61.71
EPS Est.
-$124.26
EPS Surpr.
+50.3%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$1.59
EPS Est.
-$5.96
EPS Surpr.
+73.3%
Revenue
—
Q2 FY2025
Apr 1, 2025
EPS Actual
-$1.75
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 19, 2024
EPS Actual
-$180.00
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.62 | $-0.62 | $-0.62 | 1 |
| Q3 FY2028 | $-0.56 | $-0.56 | $-0.56 | 1 |
| Q2 FY2028 | $-0.52 | $-0.52 | $-0.52 | 1 |
| Q1 FY2028 | $-1.06 | $-1.06 | $-1.06 | 1 |
| Q4 FY2027 | $-0.90 | $-0.90 | $-0.90 | 1 |
| Q3 FY2027 | $-0.81 | $-0.81 | $-0.81 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +75.0% | $0.03 | $0.03 | -1.50% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +0.0% | $0.04 | $0.04 | -4.53% |
| ▼ Q4 FY2025 | Nov 19, 2025 | -1097.4% | $0.06 | $0.06 | -1.80% |
| ▲ Q3 FY2025 | Aug 22, 2025 | +50.3% | $8.30 | $8.30 | +0.00% |
| ▲ Q2 FY2025 | May 15, 2025 | +73.3% | $11.50 | $11.67 | +1.48% |
| — Q2 FY2025 | Apr 1, 2025 | — | $14.60 | $14.40 | -1.37% |
| — Q4 FY2024 | Nov 19, 2024 | — | $479.40 | $516.20 | +7.68% |
| — Q3 FY2024 | Aug 14, 2024 | — | $314.00 | $296.00 | -5.73% |
Q2 FY2026-1.50%
Report Date
May 15, 2026
EPS Beat/Miss
+75.0%
Price Before
$0.03
Price After
$0.03
Q1 FY2026-4.53%
Report Date
Feb 25, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.04
Price After
$0.04
Q4 FY2025-1.80%
Report Date
Nov 19, 2025
EPS Beat/Miss
-1097.4%
Price Before
$0.06
Price After
$0.06
Q3 FY2025+0.00%
Report Date
Aug 22, 2025
EPS Beat/Miss
+50.3%
Price Before
$8.30
Price After
$8.30
Q2 FY2025+1.48%
Report Date
May 15, 2025
EPS Beat/Miss
+73.3%
Price Before
$11.50
Price After
$11.67
Q2 FY2025-1.37%
Report Date
Apr 1, 2025
EPS Beat/Miss
—
Price Before
$14.60
Price After
$14.40
Q4 FY2024+7.68%
Report Date
Nov 19, 2024
EPS Beat/Miss
—
Price Before
$479.40
Price After
$516.20
Q3 FY2024-5.73%
Report Date
Aug 14, 2024
EPS Beat/Miss
—
Price Before
$314.00
Price After
$296.00
Avg Beat Reaction-1.14%
Avg Miss Reaction-1.80%
Beat Rate4 / 8 quarters
Largest Move+7.68% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CERO ends December
CERo Therapeutics Holdings, Inc. (CERO) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.20 — beating the analyst consensus of $-0.80 by +75.0%. CERO has beaten EPS estimates for 2 consecutive quarters. The next CERO earnings date is expected around September 1, 2026.
Each quarter, investors track CERO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CERO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CERO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CERO earnings · 5 questionsCERo Therapeutics Holdings, Inc.'s next earnings report is expected around September 1, 2026. CERO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CERO historically reports after market close (AMC).
CERO earnings datewhen is CERO earningsCERO next earnings datewhen does CERO report earningsCERO earnings calendar
▸ Source: FMP · CERo Therapeutics Holdings, Inc. SEC filings · US GAAP · CERo Therapeutics Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026